Einzeltreffer — DigiBib

Objective: Metastatic castration resistant-prostate cancer (mCRPC) is deadly condition that remains incurable despite various therapies. Initial studies have shown promising results with Lutetium-177 prostate-specific membrane antigen ( 177 Lu-PSMA) therapy for advanced prostate cancer. However, most of the published efficacy and safety data is retrospective. The purpose of the study was to prospectively evaluate the therapeutic efficacy and safety results of 177 Lu-PSMA therapy in mCRPC patients after 2 cycles.

Methods: Twenty-five patients of mCRPC, treated with standard care treatment were enrolled for 2 cycles of 177 Lu-PSMA therapy. Prostate-specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) performance status, Visual Analogue Score (VAS) and Analgesic Quantification Scale (AQS) for efficacy and hemoglobin, total leukocyte, platelets and serum creatinine for toxicity were recorded pre and post-therapy. Paired sample t-test was used for statistical analysis.

Results: Treated patients with mean PSA level of 157 ng/ml received mean dose of 6.84 GBq of 177 Lu-PSMA. For PSA, partial response (PR) was seen in 11/25 (44%), stable disease (SD) in 8/25 (32%) and progressive disease (PD) in 6/25 (24%) patients. Grade 1 and 2 hemoglobin toxicity was seen in 5/25 (20%) and 6/25 (24%) patients respectively. No patient developed grade 3 or 4 bone marrow toxicities. Grade 1 and 2 nephrotoxicity was seen in 1 patient each. Statistically significant difference was seen in ECOG, VAS and AQS scores ( P < 0.001). No significant nephrotoxicity was observed ( P = 0.558).

Conclusion: Efficacy and safety of 177 Lu-PSMA therapy after 2 cycles have shown significant PSA response and pain palliation in heavily pretreated mCRPC patients.

Titel:	Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.
Autor/in / Beteiligte Person:	Parveen, A ; Fatima, A ; Fatima, I ; Khan, IU ; Shahid, A
Zeitschrift:	Nuclear medicine communications, Jg. 44 (2023-10-01), Heft 10, S. 876-887
Veröffentlichung:	London : Lippincott Williams & Wilkins ; <i>Original Publication</i>: London : Chapman and Hall in association with the British Nuclear Medicine Society, c1980-, 2023
Medientyp:	academicJournal
ISSN:	1473-5628 (electronic)
DOI:	10.1097/MNM.0000000000001735
Schlagwort:	Male Humans Retrospective Studies Radiopharmaceuticals therapeutic use Dipeptides adverse effects Treatment Outcome Lutetium adverse effects Heterocyclic Compounds, 1-Ring Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant radiotherapy Prostatic Neoplasms, Castration-Resistant drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Nucl Med Commun] 2023 Oct 01; Vol. 44 (10), pp. 876-887. <i>Date of Electronic Publication: </i>2023 Jul 14. MeSH Terms: Prostate-Specific Antigen* ; Prostatic Neoplasms, Castration-Resistant* / radiotherapy ; Prostatic Neoplasms, Castration-Resistant* / drug therapy ; Male ; Humans ; Retrospective Studies ; Radiopharmaceuticals / therapeutic use ; Dipeptides / adverse effects ; Treatment Outcome ; Lutetium / adverse effects ; Heterocyclic Compounds, 1-Ring References: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7–30. ; Globocan. Cancer incidence and mortality worldwide. International Agency for Research on Cancer; 2020. https://gco.iarc.fr . [Accessed 8 April 2023]. ; Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424. ; Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian Men. Nat Rev Urol 2021; 18:282–301. ; Jemal A, Seigel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277–300. ; Sarto O, Bono JD, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration resistant prostate cancer. N Eng J Med 2021; 385:1091–1103. ; Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIGO guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration resistant prostate cancer. Eur Url 2017; 71:630–642. ; Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with Enzalutamidein prostate cancer after chemotherapy. N Eng J Med 2012; 367:1187–1197. ; de Bono JS, Oudard S, Ozguroglu M, Hensen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration - resistance prostate cancer progressing after docetexale treatment; a randomized open-label trial. Lancet 2010; 376:1147–1154. ; Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetexale and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Eng J Med 2004; 351:1513–1520. ; Parkar C, Sartor O. Radium 223 in prostate cancer. N Eng. J Med 2013; 369:213–223. ; Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German Multicenter Study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58:85–90. ; Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of 177 Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med 2019; 60:955–962. ; Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [ 177 Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging 2021; 48:113–122. ; Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2019; 213:275–285. ; Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al.; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (Thera P): randomised, open-label, phase 2 trial. Lancet 2021; 397:797–804. ; Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [ 177 Lu]-PSMA-617 radio- nuclide treatment in patients with metastatic castration-resistant prostate cancer (Lu-PSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19:825–833. ; Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing (177)Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging 2021; 48:103–112. ; Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMARLT). Eur J Nucl Med Mol Imaging 2019; 46:2536–2544. ; Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. Lu-PSMA-617 radioligand therapy of metastatic castration resistant prostate cancer: Initial 254-patients results from a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging 2019; 49:1075–1085. ; Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA Ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med 2015; 56:1697–1705. ; Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol 2012; 199:278–291. ; Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:471–495. ; Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer: a Multicenter retrospective analysis. J Nucl Med 2016; 57:1334–1338. ; Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, et al. Efficacy and safety of 177 Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - a prospective study. World J Nucl Med 2019; 18:258–265. ; Sanli Y, Simsek DH, Sanli O, Subramaniam RM, Kendi AT. 177 Lu-PSMA therapy in metastatic castration-resistance prostate cancer. Biomedicines 2021; 9:430. ; Gupta M, Choudhury PS, Rawal S, Karthikeyan G, Talwar V, Dutta K, et al. Safety profile and therapeutic efficacy of one cycle of Lu177-PSMA in end-stage metastatic castration resistant prostate cancer patients with low performance status. J Nucl Med Mol Imaging 2019; 53:423–431. Substance Nomenclature: BRH40Y9V1Q (Lutetium-177) ; EC 3.4.21.77 (Prostate-Specific Antigen) ; 0 (Radiopharmaceuticals) ; 0 (Dipeptides) ; 5H0DOZ21UJ (Lutetium) ; 0 (Heterocyclic Compounds, 1-Ring) Entry Date(s): Date Created: 20230713 Date Completed: 20230914 Latest Revision: 20230914 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.